Mianserin hydrochloride: a new anti-depressant drug.
The tetracyclic anti-depressant drug mianserin hydrochloride has been assessed in an open clinical study in 24 psychiatric out-patients, who were prescribed 30 mg. mianserin daily, and were rated on the Hamilton Rating Scale and on the Wakefield Self-Assessment Inventory on day 0, before starting therapy, and on days 7 and 28 of their treatment. The results support the view that mianserin has anti-depressant properties, and the patients' self-rating scores confirm that the level of anti-depressant action is similar to amitriptyline. Drowsiness was the only side effect reported.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D003984:Dibenzazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008803:Mianserin / Q000627:therapeutic use*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
D000928:Antidepressive Agents; D003984:Dibenzazepines; D008803:Mianserin